148 related articles for article (PubMed ID: 9264051)
1. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso A; Spinà E; Campo G; Facciolă G; Ferlito M; Zuccaro P; Perucca E; Caputi AP
Pharmacol Res; 1997 Apr; 35(4):335-9. PubMed ID: 9264051
[TBL] [Abstract][Full Text] [Related]
2. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
3. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
4. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol.
Suzuki Y; Someya T; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Ther Drug Monit; 2001 Aug; 23(4):363-8. PubMed ID: 11477317
[TBL] [Abstract][Full Text] [Related]
5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
6. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Ulrich S; Neuhof S; Braun V; Meyer FP
Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
[TBL] [Abstract][Full Text] [Related]
7. [Involvement of cytochromeP4503A4 in the metabolism of haloperidol and bromperidol].
Furukori H
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):9-14. PubMed ID: 9592806
[TBL] [Abstract][Full Text] [Related]
8. Amoxapine as an antipsychotic: comparative study versus haloperidol.
Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
[TBL] [Abstract][Full Text] [Related]
9. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
Spina E; Avenoso A; Facciolà G; Fabrazzo M; Monteleone P; Maj M; Perucca E; Caputi AP
Int Clin Psychopharmacol; 1998 May; 13(3):141-5. PubMed ID: 9690983
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
[TBL] [Abstract][Full Text] [Related]
11. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
12. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
[TBL] [Abstract][Full Text] [Related]
13. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
14. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.
Someya T; Suzuki Y; Shimoda K; Hirokane G; Morita S; Yokono A; Inoue Y; Takahashi S
Psychiatry Clin Neurosci; 1999 Oct; 53(5):593-7. PubMed ID: 10595685
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
Spina E; Avenoso A; Scordo MG; Ancione M; Madia A; Gatti G; Perucca E
J Clin Psychopharmacol; 2002 Aug; 22(4):419-23. PubMed ID: 12172343
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study.
Zhang ZJ; Kang WH; Li Q; Wang XY; Yao SM; Ma AQ
Schizophr Res; 2006 Dec; 88(1-3):102-10. PubMed ID: 16959472
[TBL] [Abstract][Full Text] [Related]
17. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
[TBL] [Abstract][Full Text] [Related]
18. Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia.
Convit A; Volavka J; Czobor P; de Asis J; Evangelista C
Am J Psychiatry; 1994 Jan; 151(1):49-56. PubMed ID: 8267134
[TBL] [Abstract][Full Text] [Related]
19. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
[TBL] [Abstract][Full Text] [Related]
20. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
